Medical Advocates
Didanosine (Videx)
 
Journal Citations

General Reports           Adolescent/Adult Treatment   
 Formulations                Therapeutic Strategies
 Animal Studies
Safety
 Dosage
 Clinical Pharmacology
 Pharmacokinetics
 Drug/Drug Interactions
 Viral Dynamics
 Resistance
 Diagnostics/Monitoring
 Adverse Events
DDI Main Page Main New/Newsworthy  Home Page
Last Update:  December 30, 2011
 Documents identified with this icon  are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
Perinatal  Data are integrated with Perinatal Conference Data in the Perinatal Data Page. Pediatric Data are integrated with
Pediatric Conference Data in the Pediatric Data Page
General Reports
       
 
Abacavir, didanosine and tenofovir do not induce inflammatory, apoptotic or oxidative stress genes in
coronary endothelial cells.
 Kim C, Gupta SK, Green L, et al
Antivir Ther. 2011;16(8):1335-9.
Abstract


Abacavir and didanosine induce the interaction between human leukocytes and
endothelial cells through Mac-1 upregulation.
 De Pablo C, Orden S, Apostolova N, et al 
AIDS. 2010 May 6.
 Abstract

A WEEK IN REVIEW FEATURED REPORT
Effect of food on the antiviral activity of didanosine enteric-coated capsules: a pilot
comparative study.
 Hernández-Novoa B, Antela A, Gutiérrez C, et al
HIV Med. 2008 Feb 21
 Abstract

Semen Quality and Drug Concentrations in Seminal Plasma of Patients Using a Didanosine or
Didanosine Plus Tenofovir Containing Antiretroviral Regimen.
 Lowe SH, van Leeuwen E, Droste JA, et al  
 Ther Drug Monit. 2007 Oct;29(5):566-570.
 Abstract
Formulations
       
 
Magnitude and Duration of Elevated Gastric pH in Patients Infected with Human
Immunodeficiency Virus After Administration of Chewable, Dispersible, Buffered Didanosine
Tablets.
 Depestel DD, Kazanjian PH, Cinti SK, et al 
Pharmacotherapy. 2004 Nov;24(11):1539-45.
 Abstract

FULL-TEXT ARTICLE
Pharmacokinetics and gamma scintigraphy evaluation of two enteric coated formulations of
didanosine in healthy volunteers.
 Damle B, Ullah I, Doll W,et al. .
 Br J Clin Pharmacol 2002 Sep;54(3):255-61
Paper

Development of sustained release matrix tablets of didanosine containing methacrylic and
ethylcellulose polymers.  
 Sa'nchez-Lafuente C, Teresa Faucci M, Ferna'ndez-Are'valo M, et al.
Int J Pharm  2002 Mar 2;234(1-2):213-221
 Abstract
Animal Studies
       
  Didanosine causes sensory neuropathy in an HIV/AIDS animal model: impaired mitochondrial and
neurotrophic factor gene expression.
 Zhu Y, Antony JM, Martinez JA, et al
 Brain. 2007 Jul 6
 Abstract
Safety
       
  A WEEK-IN-REVIEW FEATURED REPORT
Short-Term Safety and Tolerability of Didanosine Combined with High- versus Low-Dose Tenofovir
Disproxil Fumarate in Ambulatory HIV-1-Infected Persons.
Young B, Weidle PJ, Baker RK , et al
AIDS Patient Care STDS. 2006 Apr;20(4):238-44.
Abstract
Dosage
       
  HAART with didanosine once versus twice daily: adherence and efficacy.
 Roca B, Lapuebla C, Vidal-Tegedor B. 
Int J Infect Dis. 2005 Jul;9(4):195-200.
 Abstract
Clinical Pharmacology: General Reports
       
  Pharmacological and clinical properties of didanosine (VIDEX), a nucleoside reverse
transcriptase inhibitor
Okiyama M, Kawashima H, Fukunishi S.
 Nippon Yakurigaku Zasshi 2002 Aug;120(2):115-22
 Abstract		  
Pharmacokinetics
       
 
FULL TEXT ARTICLE
 A new model for the population pharmacokinetics of didanosine in healthy subjects.
 Velasque LS, Estrela RC, Suarez-Kurtz G, Struchiner CJ. 
Braz J Med Biol Res. 2007 Jan;40(1):97-104.
 Paper
 
Penetration of didanosine in semen of HIV-1-infected men.
Cruciani M, Liuzzi G, Chirianni A, et al
 J Antimicrob Chemother. 2006 Mar 23;
Abstract

Eudragit RS-PM and Ethocel 100 Premium: influence over the behavior of didanosine inert matrix system.
Sanchez-Lafuente C, Rabasco AM, Alvarez-Fuentes J, et al.
Farmaco 2002 Aug;57(8):649-56
 Abstract

Pharmacological and clinical properties of didanosine (VIDEX), a nucleoside reverse transcriptase inhibitor
 Okiyama M, Kawashima H, Fukunishi S.
 Nippon Yakurigaku Zasshi 2002 Aug;120(2):115-22
 Abstract

FULL-TEXT ARTICLE
 Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency
virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials
Group Protocol 241 Investigators.
Zhou XJ, Sheiner LB, D'Aquila RT, et al.
Antimicrob Agents Chemother 1999 Jan;43(1):121-128
 Paper

  
Drug/Drug Interactions
       
 
Interactions between Buprenorphine and Antiretrovirals: Nucleos(t)ide Reverse Transcriptase
Inhibitors (NRTI) Didanosine, Lamivudine, and Tenofovir.
 Baker J, Rainey PM, Moody DE,  et al 
Am J Addict. 2010 Jan 1;19(1):17-29.
 Abstract

CD4+ Cell Count Decline Despite HIV Suppression: A Probable Didanosine-Valganciclovir
Interaction .
 Tseng AL, Salit IE.  
Ann Pharmacother. 2007 Mar 6;
 Abstract
 
Measurement of Intracellular Didanosine and Tenofovir Phosphorylated Metabolites and Possible
Interaction of the Two Drugs in Human Immunodeficiency Virus-Infected Patients.
 Pruvost A, Negredo E, Benech H, et al 
Antimicrob Agents Chemother. 2005 May;49(5):1907-1914
 Abstract
 
Pancreatitis treated with didanosine and tenofovir disoproxil fumarate.
Blanchard JN, Wohlfeiler M, Canas A, et al 
Clin Infect Dis. 2003 Sep 1;37(5):e57-62.
 Abstract
 
Effect of Tenofovir on Didanosine Absorption in Patients with HIV.
Pecora Fulco P, Kirian MA.
 Ann Pharmacother. 2003 Sep;37(9):1325-1328.
 Abstract

FULL-TEXT ARTICLE
 If taken 1 hour before indinavir (IDV), didanosine does not affect IDV exposure, despite
persistent buffering effects.
Shelton MJ, Mei H, Hewitt RG, Defrancesco R.
Antimicrob Agents Chemother 2001 Jan;45(1):298-300
 Paper
 

  
  Improved Interpretation of Genotypic Changes in the HIV-1 Reverse Transcriptase
Coding Region That Determine the Virological Response to Didanosine.
 De Luca A, Giambenedetto SD, Trotta MP, et al 
J Infect Dis. 2007 Dec 1;196(11):1645-1653.
 Abstract
   
  Antiviral activity of enteric-coated Didanosine, Stavudine, and nelfinavir versus Zidovudine
plus Lamivudine and nelfinavir.
 Gathe Jr J, Badaro R, Grimwood A, et al.
J Acquir Immune Defic Syndr 2002 Dec 1;31(4):399-403
 Abstract
Resistance
       
 
A WEEK IN REVIEW FEATURED REPORT
Initiatives for Developing and Comparing Genotype Interpretation Systems: External Validation of Existing
Systems for Didanosine against Virological Response.
Assoumou L, Brun-Vézinet F, Cozzi-Lepri A, et al
J Infect Dis. 2008 Jul 3
 Abstract
 
Presence of M184I/V in minor HIV-1 populations of patients with lamivudine and/or didanosine
treatment failure.
Svedhem V, Bergroth T, Lidman K, Sönnerborg A.
HIV Med. 2007 Nov;8(8):504-10.
 Abstract
 
Low-Level K65R Mutation in HIV-1 Reverse Transcriptase of Treatment-Experienced Patients
Exposed to Abacavir or Didanosine.
 Svarovskaia ES, Margot NA, Bae AS, et al  
J Acquir Immune Defic Syndr. 2007 Jul 19
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Phenotypic Susceptibility to Didanosine Is Associated with Antiviral Activity in Treatment-
Experienced Patients with HIV-1 Infection.
 Flandre P, Chappey C, Marcelin AG, et al 
J Infect Dis. 2007 Feb 1;195(3):392-8.
Abstract
 
Clinical Impact of the M184V Mutation on Switching to Didanosine or Maintaining Lamivudine
Treatment in Nucleoside Reverse-Transcriptase Inhibitor-Experienced Patients.
Winters MA, Bosch RJ, Albrecht MA, et al
J Infect Dis. 2003 Aug 15;188(4):537-40.
 Abstract

Genotypic and phenotypic resistance patterns in early-stage HIV-1-infected patients failing
initial therapy with stavudine, didanosine and nevirapine.
 Vidal C, Arnedo M, Garcia F, et al.   
Antivir Ther 2002 Dec;7(4):283-7
 Abstract

Comparison of Genotypic and Phenotypic Resistance Patterns of Human Immunodeficiency Virus
Type 1 Isolates from Patients Treated with Stavudine and Didanosine or Zidovudine and Lamivudine.
Picard V, Angelini E, Maillard A, et al.
Infect Dis 2001 Sep 15;184(6):781-784
 Abstract

Development of drug resistance in patients receiving combinations of zidovudine, didanosine and
nevirapine.
Conway B, Wainberg MA, Hall D, et al.
AIDS 2001 Jul 6;15(10):1269-1274
 Abstract

FULL-TEXT ARTICLE
 Decreased processivity of human immunodeficiency virus type 1 reverse transcriptase
(RT) containing didanosine-selected mutation Leu74Val: a comparative analysis of RT
variants Leu74Val and lamivudine-selected Met184Val. 
Sharma PL, Crumpacker CS.
J Virol 1999 Oct;73(10):8448-8456
 Paper
 
Diagnostics/Monitoring
       
 
Development of a didanosine genotypic resistance interpretation system based on large derivation
and validation datasets.
Assoumou L, Cozzi-Lepri A, Brun-Vézinet F 
AIDS. 2009 Oct 27.
Abstract

Determination of abacavir, amprenavir, didanosine, efavirenz, nevirapine, and stavudine concentration
in human plasma by MALDI-TOF/TOF.
 Notari S, Mancone C, Alonzi T, et al  
J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Jan 16
Abstract
 
Determination of didanosine in maternal plasma, amniotic fluid, fetal and placental tissues by high-
performance liquid chromatography-tandem mass spectrometry.
 Clark TN, White CA, Bartlett MG.
Biomed Chromatogr. 2006 Jun;20(6-7):605-11
 Abstract
 
Monitoring of didanosine and stavudine intracellular trisphosphorylated anabolite concentrations in
HIV-infected patients.
Becher F, Landman R, Mboup S, et al.
AIDS. 2004 Apr 12;18(2):181-187.
 Abstract

Determination of ddATP Levels in Human Immunodeficiency Virus-Infected Patients Treated with
Dideoxyinosine.
Le Saint C, Terreux R, Duval D
Antimicrob Agents Chemother. 2004 Feb; 48(2): 589-595.
 Abstract
Adolescent/Adult Treatment
       
HCV/HIV
 
  Didanosine, interferon-alfa and ribavirin: a highly synergistic combination with potential activity
against HIV-1 and hepatitis C virus.
 Klein MB, Campeol N, Lalonde RG, et al.  
AIDS 2003 May 2;17(7):1001-1008
 Abstract		  

HIV
 
 
Long-term effectiveness and safety of didanosine combined with lamivudine and
efavirenz or nevirapine in antiretroviral-naive patients: a 9-year cohort study in Senegal.
Laurent C, Tchatchueng Mbougua JB,  et al
Trop Med Int Health. 2010 Nov 19.
Abstract

A WEEK IN REVIEW FEATURED REPORT
Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine
and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohort.
Crespo M, Ribera E, Suárez-Lozano I, et al 
J Antimicrob Chemother. 2008 Nov 6.
Abstract
 
Didanosine, Lamivudine, and Efavirenz versus Zidovudine, Lamivudine, and Efavirenz for the Initial Treatment
of HIV Type 1 Infection: Final Analysis (48 Weeks) of a Prospective, Randomized, Noninferiority Clinical Trial,
GESIDA 3903.
 Berenguer J, González J, Ribera E, et al 
Clin Infect Dis. 2008 Sep 9. [
 Abstract
 
A WEEK IN REVIEW FEATURED REPORT
Long-Term Assessment of Didanosine, Lamivudine, and Efavirenz in Antiretroviral-Naive
Patients: 3-Year Follow-Up.
 Santos J, Palacios R, Lozano F, et al 
AIDS Res Hum Retroviruses. 2008 Jan;24(1):24-26.
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Didanosine, lamivudine-emtricitabine and efavirenz as initial therapy in naive patients.
 Palacios R, Aguilar I, Hidalgo A, Santos J.
Expert Rev Anti Infect Ther. 2006 Dec;4(6):965-971.
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir.
 Barreiro P, Soriano V. 
J Antimicrob Chemother. 2006 Mar 10;
Abstract
 
Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz:
12-week results from a randomized trial.
 Maitland D, Moyle G, Hand J, et al
AIDS. 2005 Jul 22;19(11):1183-8.
Abstract
 
Body Composition and Metabolic Changes in Antiretroviral-Naive Patients Randomized to
Didanosine and Stavudine vs. Abacavir and Lamivudine.
 Shlay JC, Visnegarwala F, Bartsch G,et al 
J Acquir Immune Defic Syndr. 2005 Feb 1;38(2):147-155
 Abstract
 
Early virological failure in treatment-naive HIV-infected adults receiving didanosine and tenofovir
plus efavirenz or nevirapine.
 Leon A, Martinez E, Mallolas J,22.et al 
AIDS. 2005 Jan 28;19(2):213-5.
 Abstract
 
A Proof-of-Concept Study of Short-Cycle Intermittent Antiretroviral Therapy with a Once-Daily
Regimen of Didanosine, Lamivudine, and Efavirenz for the Treatment of Chronic HIV Infection.
 Dybul M, Nies-Kraske E, Dewar R, et al.
J Infect Dis. 2004 Jun 1;189(11):1974-82.
 Abstract
 
Antiviral activity of enteric-coated Didanosine, Stavudine, and nelfinavir versus Zidovudine plus
Lamivudine and nelfinavir.
 Gathe Jr J, Badaro R, Grimwood A, et al.
J Acquir Immune Defic Syndr 2002 Dec 1;31(4):399-403
 Abstract
 
Tolerability of enteric-coated didanosine capsules compared with didanosine tablets in adults
with hiv infection.
 Kunches LM, Reinhalter NE, Marquis A, et al .
Acquir Immune Defic Syndr 2001 Oct 1;28(2):150-3
 Abstract
 
A pilot trial of indinavir, ritonavir, didanosine, and lamivudine in a once-daily four-drug regimen for
HIV infection.
Mole L, Schmidgall D, Holodniy M.
J Acquir Immune Defic Syndr 2001 Jul 1;27(3):260-265
 Abstract
 
Therapeutic Strategies
         
 
Didanosine in HIV-1-Infected Patients Experiencing Failure of Antiretroviral Therapy: A
Randomized Placebo-Controlled Trial.
 Molina JM, Marcelin AG, Pavie J. et al
J Infect Dis. 200Abstract5 Mar 15;191(6):840-7.
 Abstract

A randomized trial to investigate the recycling of stavudine and didanosine with and without
hydroxyurea in salvage therapy (RESTART).
 Stebbing J, Nelson M, Orkin C, et al.
Antimicrob Chemother. 2004 Feb 4
 Abstract

DDI Main Page Main New/Newsworthy  Home Page

Journal Papers, Abstracts, and Commentaries